JP2006527982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527982A5 JP2006527982A5 JP2006515723A JP2006515723A JP2006527982A5 JP 2006527982 A5 JP2006527982 A5 JP 2006527982A5 JP 2006515723 A JP2006515723 A JP 2006515723A JP 2006515723 A JP2006515723 A JP 2006515723A JP 2006527982 A5 JP2006527982 A5 JP 2006527982A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- substitution
- amino acid
- a3ay
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 31
- 102220494690 Small vasohibin-binding protein_K32E_mutation Human genes 0.000 claims 18
- 102220494687 Small vasohibin-binding protein_R36E_mutation Human genes 0.000 claims 18
- 230000037431 insertion Effects 0.000 claims 11
- 238000003780 insertion Methods 0.000 claims 11
- 102220595361 Anamorsin_A34E_mutation Human genes 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 238000001727 in vivo Methods 0.000 claims 5
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 108010054265 Factor VIIa Proteins 0.000 claims 3
- 230000004988 N-glycosylation Effects 0.000 claims 3
- 229940012414 factor viia Drugs 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 229940099816 human factor vii Drugs 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006251 gamma-carboxylation Effects 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47978003P | 2003-06-19 | 2003-06-19 | |
| US60/479,780 | 2003-06-19 | ||
| DKPA200400930 | 2004-06-15 | ||
| DKPA200400930 | 2004-06-15 | ||
| PCT/DK2004/000428 WO2004111242A1 (en) | 2003-06-19 | 2004-06-18 | FACTOR VII OR VIIa GLA DOMAIN VARIANTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011277848A Division JP5580283B2 (ja) | 2003-06-19 | 2011-12-20 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006527982A JP2006527982A (ja) | 2006-12-14 |
| JP2006527982A5 true JP2006527982A5 (enExample) | 2007-07-19 |
| JP4915918B2 JP4915918B2 (ja) | 2012-04-11 |
Family
ID=33553697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Expired - Fee Related JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
| JP2011277848A Expired - Fee Related JP5580283B2 (ja) | 2003-06-19 | 2011-12-20 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011277848A Expired - Fee Related JP5580283B2 (ja) | 2003-06-19 | 2011-12-20 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20050164932A1 (enExample) |
| EP (1) | EP1644504B8 (enExample) |
| JP (2) | JP4915918B2 (enExample) |
| KR (1) | KR101191779B1 (enExample) |
| CN (1) | CN1839203B (enExample) |
| AT (1) | ATE458057T1 (enExample) |
| AU (2) | AU2004247799B2 (enExample) |
| BR (1) | BRPI0411650A (enExample) |
| CA (1) | CA2529828C (enExample) |
| CY (1) | CY1109984T1 (enExample) |
| DE (1) | DE602004025576D1 (enExample) |
| DK (1) | DK1644504T3 (enExample) |
| ES (1) | ES2338425T3 (enExample) |
| HR (1) | HRP20100264T1 (enExample) |
| IL (1) | IL172364A (enExample) |
| MX (1) | MXPA05013769A (enExample) |
| NZ (2) | NZ573412A (enExample) |
| PL (1) | PL1644504T3 (enExample) |
| PT (1) | PT1644504E (enExample) |
| RU (1) | RU2373282C2 (enExample) |
| SI (1) | SI1644504T1 (enExample) |
| WO (1) | WO2004111242A1 (enExample) |
| ZA (1) | ZA200600539B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003521930A (ja) * | 2000-02-11 | 2003-07-22 | マキシゲン・エイピーエス | 第ＶＩＩ因子または第ＶＩＩａ因子様分子 |
| CN1665925A (zh) * | 2002-04-30 | 2005-09-07 | 马克西根控股公司 | 凝血因子Ⅶ或Ⅶa多肽变体 |
| AU2004221761B2 (en) * | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| EP1644504B8 (en) | 2003-06-19 | 2010-06-02 | Bayer HealthCare LLC | Factor vii or viia gla domain variants |
| DK1781782T3 (da) | 2004-08-17 | 2010-08-23 | Csl Behring Gmbh | Modificerede vitamin K-afhængige polypeptider |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| EP1904528B1 (en) | 2005-07-13 | 2012-10-31 | Novo Nordisk Health Care AG | Host cell protein knock-out cells for production of therapeutic proteins |
| DK1907540T3 (da) * | 2005-07-22 | 2013-03-11 | Bayer Healthcare Llc | Aktivering af faktor VII i opløsning |
| EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| US20090055942A1 (en) | 2005-09-14 | 2009-02-26 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
| TW200804416A (en) * | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
| JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
| FR2910969B1 (fr) * | 2006-12-29 | 2009-02-27 | Lab Francais Du Fractionnement | Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon |
| EP1952822A1 (en) * | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Factor VII polypeptides with increased affinity to platelets |
| UA101155C2 (ru) | 2007-04-13 | 2013-03-11 | Каталист Байосайенс, Инк. | Модифицированный полипептид фактора vii (fvii) и его применение |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| WO2010149172A2 (en) | 2009-06-24 | 2010-12-29 | Rigshospitalet | SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |
| FR2947181B1 (fr) * | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| CA3185756A1 (en) * | 2012-12-24 | 2014-07-03 | Coagulant Therapeutics Corporation | Short-acting factor vii polypeptides |
| CA3128999C (en) * | 2013-03-15 | 2023-09-12 | GLAdiator Biosciences, Inc. | Gla domains as targeting agents |
| CN104211802B (zh) * | 2013-05-29 | 2018-07-27 | 成都渊源生物科技有限公司 | 人凝血因子轻链蛋白及其应用 |
| SG11201704706RA (en) | 2014-12-10 | 2017-07-28 | Opko Biologics Ltd | Methods of producing long acting ctp-modified growth hormone polypeptides |
| EP3442554A4 (en) * | 2016-04-14 | 2019-12-04 | Iconic Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION |
| WO2018011799A1 (en) | 2016-07-11 | 2018-01-18 | Opko Biologics Ltd. | Long-acting coagulation factor vii and methods of producing same |
| EP3679127A1 (en) | 2017-09-05 | 2020-07-15 | GLAdiator Biosciences, Inc. | Delivery of payloads to stem cells |
| CN114728044A (zh) | 2019-08-15 | 2022-07-08 | 介控生化科技公司 | 用于皮下施用和按需求治疗的经修饰的因子vii多肽 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA862768B (en) * | 1985-04-17 | 1986-12-30 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| FI882746A7 (fi) | 1987-06-12 | 1988-12-13 | Hoechst Japan | Hybridiproteiini C ja menetelmä sen valmistamiseksi. |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| ES2052368T3 (es) | 1990-01-26 | 1994-07-01 | Immuno Ag | Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso. |
| JP3330932B2 (ja) * | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5531916A (en) * | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
| EP0785273A1 (en) * | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| HU218890B (hu) | 1991-02-28 | 2000-12-28 | Novo Nordisk A/S | Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ... |
| US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| PT699075E (pt) | 1993-05-21 | 2002-05-31 | Novo Nordisk As | Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas |
| DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| JP2001523949A (ja) * | 1996-11-08 | 2001-11-27 | オクラホマ メディカル リサーチ ファウンデーション | 改変したプロテインｃおよびその使用方法 |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| EP1017794A1 (en) | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| EP1005361B1 (en) | 1997-07-18 | 2010-01-06 | Novo Nordisk Health Care AG | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| NZ511291A (en) | 1998-10-30 | 2003-08-29 | Novozymes As | A method for selecting a protein variant that has reduced immunogenicity as compared with the parent or wild-type protein |
| AU774156B2 (en) | 1998-10-30 | 2004-06-17 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| WO2000028065A1 (en) | 1998-11-06 | 2000-05-18 | Novo Nordisk A/S | Method for the production of fvii |
| WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| JP2003521930A (ja) * | 2000-02-11 | 2003-07-22 | マキシゲン・エイピーエス | 第ＶＩＩ因子または第ＶＩＩａ因子様分子 |
| US7220837B1 (en) * | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| DE60143292D1 (de) | 2000-05-03 | 2010-12-02 | Novo Nordisk Healthcare Ag | Varianten des menschlichen Koagulationsfaktors VII |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US6423826B1 (en) * | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| BR0113854A (pt) * | 2000-09-13 | 2004-07-06 | Novo Nordisk As | Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal |
| PL204888B1 (pl) | 2000-09-13 | 2010-02-26 | Novo Nordisk Healthcare Ag | Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII |
| EP1325113B1 (en) * | 2000-10-02 | 2010-04-21 | Novo Nordisk Health Care AG | Factor vii glycoforms |
| AU2002218029A1 (en) | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| WO2002077218A1 (en) | 2001-03-22 | 2002-10-03 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
| ES2376694T3 (es) | 2001-09-27 | 2012-03-16 | Novo Nordisk Health Care Ag | Polipã‰ptidos del factor vii de coagulaciã“n humano. |
| AU2002336919A1 (en) | 2001-11-02 | 2003-05-12 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| BR0215216A (pt) | 2001-12-21 | 2004-11-16 | Novo Nordisk Healthcare Ag | Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii |
| CN1665925A (zh) * | 2002-04-30 | 2005-09-07 | 马克西根控股公司 | 凝血因子Ⅶ或Ⅶa多肽变体 |
| ATE505487T1 (de) * | 2002-09-30 | 2011-04-15 | Bayer Healthcare Llc | Fvii- oder fviia-varianten mit erhöhter koagulationswirkung |
| AU2004221761B2 (en) * | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
| EP1644504B8 (en) * | 2003-06-19 | 2010-06-02 | Bayer HealthCare LLC | Factor vii or viia gla domain variants |
-
2004
- 2004-06-18 EP EP04738925A patent/EP1644504B8/en not_active Expired - Lifetime
- 2004-06-18 MX MXPA05013769A patent/MXPA05013769A/es active IP Right Grant
- 2004-06-18 WO PCT/DK2004/000428 patent/WO2004111242A1/en not_active Ceased
- 2004-06-18 RU RU2006101391/13A patent/RU2373282C2/ru not_active IP Right Cessation
- 2004-06-18 NZ NZ573412A patent/NZ573412A/en not_active IP Right Cessation
- 2004-06-18 PL PL04738925T patent/PL1644504T3/pl unknown
- 2004-06-18 DK DK04738925.9T patent/DK1644504T3/da active
- 2004-06-18 PT PT04738925T patent/PT1644504E/pt unknown
- 2004-06-18 AT AT04738925T patent/ATE458057T1/de active
- 2004-06-18 CA CA2529828A patent/CA2529828C/en not_active Expired - Fee Related
- 2004-06-18 DE DE602004025576T patent/DE602004025576D1/de not_active Expired - Lifetime
- 2004-06-18 JP JP2006515723A patent/JP4915918B2/ja not_active Expired - Fee Related
- 2004-06-18 ES ES04738925T patent/ES2338425T3/es not_active Expired - Lifetime
- 2004-06-18 AU AU2004247799A patent/AU2004247799B2/en not_active Ceased
- 2004-06-18 KR KR1020057024386A patent/KR101191779B1/ko not_active Expired - Fee Related
- 2004-06-18 NZ NZ544728A patent/NZ544728A/en unknown
- 2004-06-18 SI SI200431396T patent/SI1644504T1/sl unknown
- 2004-06-18 HR HR20100264T patent/HRP20100264T1/hr unknown
- 2004-06-18 BR BRPI0411650-0A patent/BRPI0411650A/pt not_active IP Right Cessation
- 2004-06-18 CN CN2004800237774A patent/CN1839203B/zh not_active Expired - Fee Related
- 2004-12-22 US US11/021,239 patent/US20050164932A1/en not_active Abandoned
-
2005
- 2005-12-05 IL IL172364A patent/IL172364A/en not_active IP Right Cessation
-
2006
- 2006-01-19 ZA ZA2006/00539A patent/ZA200600539B/en unknown
- 2006-04-21 US US11/379,664 patent/US20060252128A1/en not_active Abandoned
- 2006-06-14 US US11/424,035 patent/US8987202B2/en not_active Expired - Fee Related
- 2006-06-14 US US11/424,030 patent/US7807638B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/643,535 patent/US20070117756A1/en not_active Abandoned
-
2010
- 2010-03-02 AU AU2010200793A patent/AU2010200793B2/en not_active Ceased
- 2010-04-23 CY CY20101100374T patent/CY1109984T1/el unknown
-
2011
- 2011-12-20 JP JP2011277848A patent/JP5580283B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006527982A5 (enExample) | ||
| JP2012105650A5 (enExample) | ||
| RU2004134726A (ru) | Варианты полипептида фактора vii или viia | |
| JP2006521098A5 (enExample) | ||
| JP2006517089A5 (enExample) | ||
| HRP20100264T1 (hr) | Varijante gla domene faktora vii ili viia | |
| JP2012095641A5 (enExample) | ||
| KR101623602B1 (ko) | 변형된 제ⅶ 인자 폴리펩티드 및 그의 용도 | |
| ES2537328T3 (es) | Polipéptidos de factor VII modificados y usos de los mismos | |
| CA2519873A1 (en) | Fvii or fviia variants | |
| RU2002124129A (ru) | Молекулы, подобные фактору vii или viia | |
| RU2396347C2 (ru) | Модифицированные витамин к-зависимые полипептиды | |
| CA2989990A1 (en) | Long-acting coagulation factors and methods of producing same | |
| KR101600158B1 (ko) | 지혈을 조절하기 위한 조성물 및 방법 | |
| US20080188400A1 (en) | Methods For Treating Bleeding | |
| US20240352090A1 (en) | Use of protein sequence capable of binding to substrate in preparation of product for inhibiting fibrin assembly | |
| JP2008502323A5 (enExample) | ||
| CN105025920A (zh) | 具有因子Xa衍生物的组织因子途径抑制剂的抑制 | |
| JP2005518801A5 (enExample) | ||
| ES2361495T3 (es) | Variantes de fvii o fviia que tienen actividad de coagulación mejorada. | |
| HK1095357B (en) | Factor vii or viia gla domain variants | |
| AU2013204377A1 (en) | Modified factor vii polypeptides and uses thereof |